Jason Butler
Stock Analyst at Citizens Capital Markets
(3.11)
# 1,161
Out of 4,784 analysts
137
Total ratings
38.24%
Success rate
1.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.59 | +277.36% | 9 | Mar 20, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.43 | +413.22% | 2 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $7.85 | +129.30% | 2 | Mar 12, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $4 | $1.50 | +166.67% | 7 | Mar 5, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $696 → $701 | $589.15 | +18.98% | 8 | Feb 28, 2025 | |
| PRTA Prothena Corporation | Reiterates: Market Outperform | $80 | $13.14 | +508.83% | 8 | Feb 21, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $29 → $33 | $13.68 | +141.23% | 1 | Feb 21, 2025 | |
| RZLT Rezolute | Maintains: Market Outperform | $8 → $9 | $2.93 | +207.17% | 8 | Feb 13, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $43.19 | +80.60% | 14 | Feb 7, 2025 | |
| VIGL Vigil Neuroscience | Reiterates: Market Outperform | $22 | $1.91 | +1,051.83% | 4 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $63.84 | +14.35% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.02 | +198.01% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $11.06 | +252.62% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.31 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.18 | +1,849.15% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.74 | +181.90% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $17.07 | +128.47% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $14.44 | +163.16% | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $1.41 | +1,460.28% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.81 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $1,200 | $0.24 | +496,177.92% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $5.71 | +1,931.52% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.50 | +157.14% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.35 | - | 1 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 → $21 | $131.81 | -84.07% | 5 | Aug 8, 2019 |
Precigen
Mar 20, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.59
Upside: +277.36%
ABIVAX Société Anonyme
Mar 18, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.43
Upside: +413.22%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $7.85
Upside: +129.30%
Esperion Therapeutics
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.50
Upside: +166.67%
argenx SE
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $589.15
Upside: +18.98%
Prothena Corporation
Feb 21, 2025
Reiterates: Market Outperform
Price Target: $80
Current: $13.14
Upside: +508.83%
Dynavax Technologies
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $13.68
Upside: +141.23%
Rezolute
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $2.93
Upside: +207.17%
Cytokinetics
Feb 7, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $43.19
Upside: +80.60%
Vigil Neuroscience
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22
Current: $1.91
Upside: +1,051.83%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $63.84
Upside: +14.35%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.02
Upside: +198.01%
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $11.06
Upside: +252.62%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.18
Upside: +1,849.15%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $6.74
Upside: +181.90%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $17.07
Upside: +128.47%
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $14.44
Upside: +163.16%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $1.41
Upside: +1,460.28%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.81
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $1,200
Current: $0.24
Upside: +496,177.92%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $5.71
Upside: +1,931.52%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.50
Upside: +157.14%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.35
Upside: -
Aug 8, 2019
Reiterates: Market Outperform
Price Target: $24 → $21
Current: $131.81
Upside: -84.07%